KNOWLEDGE, ATTITUDES AND PREFERENCES AMONG SPANISH COMMUNITY PHARMACISTS REGARDING INHALED THERAPY (THE OPTIM PHARMACY STUDY)

  • Jordi Giner Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Pere Roura Department of Clinical Epidemiology and Research, Hospital General de Vic, Vic, Barcelona, Spain
  • Berta Torres Pharmacist, Barcelona, Spain
  • Felip Burgos Respiratory Diagnostic Center, Department of Respiratory Medicine (ICR), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona, Barcelona; and Center for Biomedical Metwork Research in Respiratory Diseases (CIBERES), Spain
  • Diego Castillo Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain
  • Eduard Tarragona Medical Department, Chiesi España, S.A., L’Hospitalet de Llobregat, Barcelona, Spain
  • Vicente Plaza Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain

Abstract

Objective: To assess knowledge, attitudes, and preferences regarding inhaled therapy among Spanish community pharmacists.

Methods: An 11-item questionnaire was developed and distributed to community pharmacists throughout the country. Data collected included demographics, the source of knowledge of inhaler use, known and preferred devices, steps for correct use of metered-dose (pMDI) and dry-powder (DPI) inhalers, important variables when prescribing an inhaler device, patient education, and checking inhaler technique.

Results: Of a total of 3000 questionnaires delivered, 1722 (57.4%) were returned. The most common source of knowledge was the package insert (46.9%) followed by personal experience (33.3%). DiskusTM and TurbuhalerTM were the best-known devices (96.4% and 93.4%), and DPIs the preferred inhalers. Although more than half of the surveyed pharmacists were aware of the most important step for correct inhalation with pMDI and DPI, only 18% identified the correct answer ‘Patient’s preference’ as the most important variable when prescribing an inhaler device. Most of the respondents had inadequate knowledge of inhaled therapies. Statistically, significant differences were found according to geographical areas. Moreover, the mean score on inhaled therapy with one knowledge source was higher than for those with none (P<0.05). Additionally, patient education was poor.

Conclusion: In spite of the increasing involvement of Spanish community pharmacists in patients’ care, their knowledge of inhaler use and attitudes towards inhaled therapy needs to improve, so that they can provide better patient education.
Keywords: Inhaler devices, Inhalation techniques, Community pharmacist, Misuse of inhalers

Downloads

Download data is not yet available.

References

1. Plaza V, Calle M, Molina J, Quirce C, Sanchís J, Viejo JL, et al. External validation of the recommendations of the multidisciplinary consensus about inhaled therapies. Arch Bronconeumol 2012;48:189-96.
2. Mortensen NP, Hickey AJ. Targeting inhaled therapy beyond the lungs. Respiration 2014;88:353-4.
3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2015. Available at: http://www. ginasthma. org. Date accessed: September 15, 2015.
4. GEMA 4.0. Spanish Guideline on the Management of Asthma; 2015. Availablle from: http://www.gemasma.com/. [Last accessed on 15 Sep 2015].
5. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish guideline for COPD (GesEPOC). Arch Bronconeumol 2014;50 Suppl 1:1-16.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated; 2015. Available from: http://www.goldcopd.org/uploads/users/ files/GOLD_Report_2015_Apr2.pdf. [Last accessed on 15 Sep 2015].
7. Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PR. ADMIT series--issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Primary Care Respiratory J 2009;18:76-82.
8. Sanchis J, Corrigan C, Levy ML, Viejo JL. Inhaler devices-from theory to practice. Respir Med 2013;107:495-502.
9. Voshaar T, Spinola M, Linnane P, Campanini A, Lock D, Lafratta A, et al. Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Delivery 2014;27:363-70.
10. SEPAR-ALAT consensus for inhaled therapies. Arch Bronconeumol 2013;49 Suppl 1:2-14.
11. Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31.
12. Role of the pharmacist in improving asthma care. National Asthma Education and Prevention Program. Am J Health Syst Pharm 1995;52:1411-6.
13. Castillo D, Burgos F, Guayta R, Giner J, Lozano P, Estrada M, et al. Airflow obstruction case finding in community pharmacies: a novel strategy to reduce COPD underdiagnosis. Respir Med 2015;109:475-82.
14. Le Gouldec N, Ait Tahar H, Sonneville A. The physician-pharmacist team in the education of patients concerning inhalant therapy. Allerg Immunol 2001;33:383-7.
15. Stuurman-Bieze AGG, de Boer WO, Kokenberg MEAP, Hugtenburg JG, de Jong-van den Berg LTW, Tromp TFJ. Complex pharmaceutical care intervention in pulmonary care: part A. The process and pharmacists’ professional satisfaction. Pharm World Sci 2005;27:376-84.
16. Balter M, Ernst P, Watson W. Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. Can Respir J 2008;15 Suppl B:1B-19B.
17. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013;14:109.
18. Bosnic-Anticevich SZ, Stuart M, Mackson J, Cvetkovski B, Sainsbury E, Armour C, et al. Development and evaluation of an innovative model of inter-professional education focused on asthma medication use. BMC Med Educ 2014;14:72.
19. Plaza V, Sanchis J, Roura P, Molina J, Calle M, Quirce S, et al. Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain. J Aerosol Med Pulm Drug Delivery 2012;25:16-22.
20. Giner J, Roura P, Hernández C, Torrejón M, Peiró M, Fernández MJ, et al. Knowledge and attitudes of nurses in spain about inhaled therapy: Results of a national survey. J Aerosol Med Pulm Drug Delivery 2015. Doi:10.1089/jamp.2014.1198.
21. Gorgas Torner MQ, Pàez Vives F, Camós Ramió J, de Puig Cabrera E, Jolonch Santasusagna P, Horns Peipoch E, et al. Integrated pharmaceutical care programme in patients with chronic diseases. Farm Hosp 2012;36:229-39.
22. Van Boven JFM, Stuurman Bieze AGG, Hiddink EG, Postma MJ, Vegter S. Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Spec Pharm 2014;20:786-92.
23. Fathima M, Naik-Panvelkar P, Saini B, Armour CL. The role of community pharmacists in screening and subsequent management of chronic respiratory diseases: a systematic review. Pharm Pract 2013;11:228–45.
24. Van Boven JFM, Hiddink EG, Stuurman-Bieze AGG, Schuiling-Veninga CCM, Postma MJ, Vegter S. The pharmacists’ potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma. Int J Clin Pharm 2013;35:1075-82.
25. Zhong H, Ni XJ, Cui M, Liu XY. Evaluation of pharmacist care for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Clin Pharm 2014;36:1230–40.
26. Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol 2014;77:756-66.
27. Wright D, Twigg M, Barton G, Thornley T, Kerr C. An evaluation of a multi-site community pharmacy-based chronic obstructive pulmonary disease support service. Int J Pharm Pract 2015;23:36-43.
28. Hämmerlein A, Müller U, Schulz M. Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients. J Evaluation Clin Practice 2011;17:61-70.
29. Takemura M, Mitsui K, Ido M, Matsumoto M, Koyama M, Inoue D, et al. Impact of a network system for providing proper inhalation technique by community pharmacists. J Asthma 2012;49:535-41.
30. Toumas Shehata M, Price D, Basheti IA, Bosnic-Anticevich S. Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel group, repeated-measures study. NPJ Prim Care Respir Med 2014;24:14071.
31. Armour CL, LeMay K, Saini B, Reddel HK, Bosnic-Anticevich SZ, Smith LD, et al. Using the community pharmacy to identify patients at risk of poor asthma control and factors which contribute to this poor control. J Asthma 2011;48:914-22.
32. Armour CL, Reddel HK, LeMay KS, Saini B, Smith LD, Bosnic-Anticevich SZ, et al. Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomized trial. J Asthma 2013;50:302-9.
33. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol 2007;119:1537-8.
34. Axtell S, Haines S, Fairclough J. Effectiveness of various methods of teaching proper inhaler technique: the importance of pharmacist counseling. J Pharm Pract 2016. Doi:10.1177/0897190016628961.
35. Andrés J, Iñesta A, Huetos J, Rodrigo N. Knowledge of inhalation technique of antiasthma drugs by community pharmacists. Pharm Care Esp 2004;6:191-4.
36. Basheti IA, Armour CL, Reddel HK, Bosnic-Anticevich SZ. Long-term maintenance of pharmacists’ inhaler technique demonstration skills. Am J Pharm Educ 2009;73:32.
37. Basheti IA, Qunaibi E, Bosnic-Anticevich SZ, Armour CL, Khater S, Omas M, et al. User error with diskus and turbuhaler by asthma patients and pharmacists in Jordan and Australia. Respir Care 2011;56:1916-23.
38. Casset A, Rebotier P, Lieutier-Colas F, Glasser N, Heitz C, Saigne J, et al. Pharmacists’ role in the management of asthma: a survey of 120 pharmacists in Bas-Rhin. Rev Mal Respir 2004;21:925-33.
39. Cain WT, Cable G, Oppenheimer JJ. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy Clin Immunol 2001;108:918-20.
40. Casset A, Meunier-Spitz M, Rebotier P, Lefèvre H, Barth C, Heitz C, et al. Asthma management and inhalation techniques among community pharmacists in 2009: A comparison with the 1999 survey. J Asthma 2014;51:964-73.
41. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest 1993;104:1737-42.
42. Mickle TR, Self TH, Farr GE, Bess DT, Tsiu SJ, Caldwell FL. Evaluation of pharmacists’ practice in patient education when dispensing a metered-dose inhaler. Dalian Institute of Chem Physics 1990;24:927-30.
43. Schneider CR, Everett AW, Geelhoed E, Kendall PA, Clifford RM. Measuring the assessment and counseling provided with the supply of nonprescription asthma reliever medication: a simulated patient study. Ann Pharmacother 2009;43:1512-8.
44. Elaro A, Shah S, Armour CL, Bosnic-Anticevich S. A snapshot of pharmacist attitudes and behaviors surrounding the management of pediatric asthma. J Asthma 2015;52:957-68.
45. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001;21:1196-203.
46. Diamond SA, Chapman KR. The impact of a nationally coordinated pharmacy-based asthma education intervention. Can Respir J 2001;8:261-5.
47. Laufenberg-Horstmann E, DeVore E, Bassuener K. The coulee region community pharmacy asthma intervention study. J Am Pharm Assoc 2003;46:738-46.
48. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Counseling about Turbuhaler technique: needs assessment and effective strategies for community pharmacists. Respir Care 2005;50:617-23.
49. Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study. J Asthma 2007;44:57-64.
50. Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns 2008;72:26-33.
51. De Vries TW, van den Berg PB, Duiverman EJ, de Jong-van, den Berg LTW. Effect of a minimal pharmacy intervention on improvement of adherence to asthma guidelines. Arch Dis Child 2010;95:302-4.
52. Naik Panvelkar P, Armour C, Saini B. Community pharmacy-based asthma services--what do patients prefer? J Asthma 2010;47:1085-93.
53. Saini B, Krass I, Smith L, Bosnic-Anticevich S, Armour C. Role of community pharmacists in asthma-Australian research highlighting pathways for future primary care models. Australas Med J 2011;4:190-200.
54. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir Med 2011;105:1815-22.
55. García-Cárdenas V, Sabater-Hernández D, Kenny P, Martínez-Martínez F, Faus MJ, Benrimoj SI. Effect of a pharmacist intervention on asthma control. A cluster randomised trial. Respir Med 2013;107:1346-55.
56. Bereznicki BJ, Peterson G, Jackson S, Walters EH, George J, Stewart K, et al. Uptake and effectiveness of a community pharmacy intervention programme to improve asthma management. J Clin Pharm Ther 2013;38:212-8.
57. Ottenbros S, Teichert M, de Groot R, Griens F, Sodihardjo F, Wensing M, et al. Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients. Int J Clin Pharm 2014;36:336-44.
58. Elaro A, Shah S, Pomare LN, L Armour C, Z Bosnic-Anticevich S. PACE: Pharmacists use the power of communication in paediatric asthma. Int J Clin Pharm 2014;36:976-85.
59. Nobles J, Hutchison AM. Potential problems and solutions with inhaler use in elderly COPD patients. Consultpharm 2014;29:753-6.
60. Kaae S, Christensen ST. Exploring long-term implementation of cognitive services in the community pharmacies a qualitative study. Pharm Pract (Granada) 2012;10:151-8.
Statistics
400 Views | 515 Downloads
Citatons
How to Cite
Giner, J., P. Roura, B. Torres, F. Burgos, D. Castillo, E. Tarragona, and V. Plaza. “KNOWLEDGE, ATTITUDES AND PREFERENCES AMONG SPANISH COMMUNITY PHARMACISTS REGARDING INHALED THERAPY (THE OPTIM PHARMACY STUDY)”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 9, Sept. 2016, pp. 53-60, doi:10.22159/ijpps.2016v8i9.11796.
Section
Original Article(s)